EA
KDNY

Emerald Acquisition’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Emerald Acquisition’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-8,035
Closed -$454K – 3066
2016
Q2 		$454K Buy
+8,035
New +$488K ﹤0.01% 2510

Other funds holding KDNY

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Emerald Acquisition's KDNY Position: Q3 2016 in Review

Emerald Acquisition sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2016, closing a stake of 8,035 shares — an estimated $454K sold.

Emerald Acquisition first reported a position in KDNY in Q2 2016 and held it in 1 quarter. The position peaked at $454K in Q2 2016. 92 funds tracked by Wall St. Rank hold KDNY as of Q3 2016.

  • Emerald Acquisition reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2016 after selling out during the quarter.
  • Emerald Acquisition sold 8,035 Chinook Therapeutics, Inc. Common Stock shares in Q3 2016, an estimated $454K.
  • Emerald Acquisition first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2016 and held it in 1 quarter.
  • Emerald Acquisition's Chinook Therapeutics, Inc. Common Stock position peaked at $454K in Q2 2016.
  • 92 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.